Sep 24, 2024   SOURCE: PR NewsWire

More Than 50% of Level III & IV NICUs in U.S. Used Prolacta's 100% Human Milk-Based Products to Help Reduce Necrotizing Enterocolitis (NEC) in the Smallest Premature Infants in 2024

Prolacta Announces Major Milestone During NICU Awareness Month

DUARTE, Calif., Sept. 24, 2024 /PRNewswire/ -- Prolacta Bioscience today announced a significant milestone in premature infant nutrition. The company's human milk-based nutritional products have been used by more than 50% of Level III and Level IV neonatal intensive care units (NICUs) in the U.S. in 2024 to care for the most vulnerable premature infants - those born weighing less than 1250 g (2.75 lb).(1) The milestone signifies progress in neonatal care and the crucial role human milk plays in reducing complications, including the life-threatening intestinal disease, necrotizing enterocolitis (NEC).

Over the past 17 years, Prolacta's 100% human milk-based nutritional products (made from donor breast milk) have become an option, over the use of cow milk-based nutrition, for premature infants in the NICU born weighing less than 1250 g.

The announcement comes during NICU Awareness Month, when professional and parent organizations are raising awareness of the nutritional standards in NICUs. Leading advocates for premature infants and their families support the adoption of human milk-based nutrition in the NICU, including: the National Black Nurses Association, Association of Women's Health, Obstetric and Neonatal Nurses, NICU Parent Network, Project NICU, and Once Upon a Preemie, Inc.

"The use of Prolacta's fortifiers and formulas in NICUs across the country represents a significant advancement in neonatal care and recognition of the vital role that human milk-based nutrition plays in the survival and long-term health of extremely premature infants," said Melinda Elliott, MD, FAAP, practicing neonatologist and chief medical officer for Prolacta.

One in 10 babies are born prematurely and nearly 1 million die each year worldwide, according to the World Health Organization.(2) A recent meta-analysis, "Association of Fortification With Human Milk Versus Bovine Milk-Based Fortifiers on Short-Term Outcomes in Preterm Infants--A Meta-Analysis," found a 50% reduction in mortality among preterm infants fed human milk-based nutritional fortifiers, versus cow milk-based fortifiers.(3)

A growing body of clinical evidence demonstrates the short- and long-term health benefits to critically ill, premature infants. Compared to cow milk-based products, an Exclusive Human Milk Diet (EHMD) with Prolacta's 100% human milk-based nutritional fortifiers, has been clinically proven in numerous clinical studies to:

    --  Lower mortality and morbidity(4.5)
    --  Reduce risk of necrotizing enterocolitis (NEC)(6-8)
    --  Reduce incidence of feeding intolerance(6)
    --  Achieve adequate growth(9-11)
    --  Reduce incidence of bronchopulmonary dysplasia (BPD)(6,7,9,12)
    --  Reduce incidence of retinopathy of prematurity (ROP)(6,7,12,13)
    --  Reduce late-onset sepsis incidence(7,13) and evaluations(12)
    --  Improve long term outcomes such as neurodevelopment(14,15)
    --  Shorten stays in the neonatal intensive care unit (NICU)(6)
    --  Reduce hospital costs(6,16)

NICU Awareness Month is celebrated every September to raise awareness for the critical-care NICUs that care for premature and medically fragile newborns. For more information about Prolacta Bioscience, visit prolacta.com.

About Prolacta Bioscience
Prolacta Bioscience(®) is a global life sciences company dedicated to Advancing the Science of Human Milk(®) to improve health outcomes for critically ill and premature infants. More than 100,000 extremely premature infants worldwide(17) have benefited from Prolacta's human milk-based products, which have been evaluated in more than 30 peer-reviewed clinical studies. Operating the world's first pharmaceutical-grade human milk processing facilities, Prolacta maintains the industry's strictest quality and safety standards, with over 20 validated tests for screening and testing human milk. Prolacta's manufacturing process uses vat pasteurization to ensure pathogen inactivation while protecting nutritional composition and bioactivity. Learn more at www.prolacta.com, on X, Instagram, Facebook, and LinkedIn.

Media Contact:
Loren Kosmont
Lkosmont@prolacta.com
310-721-9444

References 

    1. Data on file; number of U.S. hospitals that used Prolacta's fortifiers
       and formulas in 2024.


    2. World Health Organization. Born too soon: decade of action on preterm
       birth. May 9, 2023. Accessed September 16, 2024.
       https://www.who.int/publications/i/item/9789240073890


    3. Galis R, Trif P, Mudura D, Mazela J, Daly MC, Kramer BW, Diggikar S.
       Association of fortification with human milk versus bovine milk-based
       fortifiers on short-term outcomes in preterm infants--a meta-analysis.
       Nutrients. 2024;16:910. https://doi.org/ 10.3390/nu16060910


    4. Lucas A, Boscardin J, Abrams SA. Preterm infants fed cow's milk-derived
       fortifier had adverse outcomes despite a base diet of only mother's own
       milk. Breastfeed Med. 2020;15(5):297-303. doi:10.1089/bfm.2019.0133


    5. Abrams SA, Schanler RJ, Lee ML, Rechtman DJ. Greater mortality and
       morbidity in extremely preterm infants fed a diet containing cow milk
       protein products. Breastfeed Med. 2014;9(6):281-285.
       doi:10.1089/bfm.2014.0024


    6. Assad M, Elliott MJ, Abraham JH. Decreased cost and improved feeding
       tolerance in VLBW infants fed an exclusive human milk diet. J Perinatol.
       2016;36(3):216-220. doi:10.1038/jp.2015.168


    7. Hair AB, Peluso AM, Hawthorne KM, et al. Beyond necrotizing enterocolitis
       prevention: improving outcomes with an exclusive human milk-based diet
       [published correction appears in Breastfeed Med. 2017 Dec;12 (10):663].
       Breastfeed Med. 2016;11(2):70-74. doi:10.1089/bfm.2015.0134


    8. Sullivan S, Schanler RJ, Kim JH, et al. An exclusively human milk-based
       diet is associated with a lower rate of necrotizing enterocolitis than a
       diet of human milk and bovine milk-based products. J Pediatr.
       2010;156(4):562-567.e1. doi:10.1016/j.jpeds.2009.10.040


    9. Huston R, Lee M, Rider E, et al. Early fortification of enteral feedings
       for infants <1250 grams birth weight receiving a human milk diet
       including human milk-based fortifier. J Neonatal Perinatal Med.
       2020;13(2):215-221. doi:10.3233/NPM-190300


    10. Huston RK, Markell AM, McCulley EA, Gardiner SK, Sweeney SL. Improving
        growth for infants <=1250 grams receiving an exclusive human milk diet.
        Nutr Clin Pract. 2018;33(5):671-678. doi:10.1002/ncp.10054


    11. Hair AB, Hawthorne KM, Chetta KE, Abrams SA. Human milk feeding supports
        adequate growth in infants <=1250 grams birth weight. BMC Res Notes.
        2013;6:459. Published 2013 Nov 13. doi:10.1186/1756-0500-6-459


    12. Delaney Manthe E, Perks PH, Swanson JR. Team-based implementation of an
        exclusive human milk diet. Adv Neonatal Care. 2019;19(6):460-467.
        doi:10.1097/ANC.0000000000000676


    13. O'Connor DL, Kiss A, Tomlinson C, et al. Nutrient enrichment of human
        milk with human and bovine milk-based fortifiers for infants born
        weighing <1250 g: a randomized clinical trial [published correction
        appears in Am J Clin Nutr. 2019 Aug 1;110(2):529] [published correction
        appears in Am J Clin Nutr. 2020 May 1;111(5):1112]. Am J Clin Nutr.
        2018;108(1):108-116. doi:10.1093/ajcn/nqy067


    14. Hair AB, Patel AL, Kiechl-Kohlendorfer U, et al. Neurodevelopmental
        outcomes of extremely preterm infants fed an exclusive human milk-based
        diet versus a mixed human milk + bovine milk-based diet: a multi-center
        study. J Perinatol. 2022;42(11):1485-1488. doi:
        10.1038/s41372-022-01513-3


    15. Bergner EM, Shypailo R, Visuthranukul C, et al. Growth, body
        composition, and neurodevelopmental outcomes at 2 years among preterm
        infants fed an exclusive human milk diet in the neonatal intensive care
        unit: a pilot study. Breastfeed Med. 2020. 15(5):304-311.
        doi:10.1089/bfm.2019.0210


    16. Ganapathy V, Hay JW, Kim JH. Costs of necrotizing enterocolitis and
        cost-effectiveness of exclusively human milk-based products in feeding
        extremely premature infants. Breastfeed Med. 2012;7(1):29-37.
        doi:10.1089/bfm.2011.0002
    17. Data on file; estimated number of premature infants fed Prolacta's
        products from January 2007 to August 2023.

View original content to download multimedia:https://www.prnewswire.com/news-releases/more-than-50-of-level-iii--iv-nicus-in-us-used-prolactas-100-human-milk-based-products-to-help-reduce-necrotizing-enterocolitis-nec-in-the-smallest-premature-infants-in-2024-302257369.html

SOURCE Prolacta Bioscience